Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A drug for the treatment of focal segmental glomerulosclerosis

A glomerulosclerosis and focal segmental technology, applied in the fields of medicine and pharmacy, can solve problems such as easy dependence and drug withdrawal reactions, poor patient tolerance and compliance, and inability to treat FSGS, achieving considerable results Economic and social benefits, good patient compliance and tolerance, good market prospects

Active Publication Date: 2020-09-11
THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] The problem to be solved by the present invention is: because the various therapeutic drugs for focal segmental glomerulosclerosis have great limitations in the use process, such as serious adverse reactions of glucocorticoids, easy to produce dependence and Drug withdrawal reaction can also cause water-salt metabolism and sugar, fat, protein metabolism disorders, severe infection, etc., poor tolerance and compliance of patients; immunosuppressants are expensive, and the curative effect is not good when used alone; The treatment effect on patients with severe clinical symptoms is not satisfactory, sometimes leading to the occurrence of drug-induced hepatitis; other symptomatic drugs can only treat and correct some accompanying symptoms, and cannot fundamentally play a therapeutic role in FSGS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug for the treatment of focal segmental glomerulosclerosis
  • A drug for the treatment of focal segmental glomerulosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] A medicine for treating focal segmental glomerulosclerosis, the medicine is made of the following raw materials in parts by weight:

[0047] Astaxanthin 15; Ginger 4500.

[0048] The preparation method is as follows:

[0049] (1) Rinse the fresh ginger with water, squeeze the juice after peeling, the supernatant of the gained juice after centrifugation utilizes an ultrafiltration membrane with a cut-off molecular weight of 600 to carry out ultrafiltration, and the obtained filter residue is freeze-dried to obtain freeze-dried ginger juice powder; The filtrate is concentrated under reduced pressure to a small volume and spray-dried to obtain ginger juice spray-dried powder;

[0050] (2) Mix the astaxanthin with the freeze-dried ginger juice powder and the spray-dried ginger juice powder prepared in the step (1), and fully mix them in a blender to obtain the drug powder.

Embodiment 2

[0052] A medicine for treating focal segmental glomerulosclerosis, the medicine is made of the following raw materials in parts by weight:

[0053] Astaxanthin 18; Ginger 5040.

[0054] The preparation method is as follows:

[0055] (1) Rinse the fresh ginger with water, squeeze the juice after peeling, and the supernatant after centrifugation of the gained juice is ultrafiltered with an ultrafiltration membrane with a molecular weight cut-off of 500, and the resulting filter residue is freeze-dried to obtain freeze-dried ginger juice powder; The filtrate is concentrated under reduced pressure to a small volume and spray-dried to obtain ginger juice spray-dried powder;

[0056] (2) Mix the astaxanthin with the freeze-dried ginger juice powder and the spray-dried ginger juice powder prepared in the step (1), and fully mix them in a blender to obtain the drug powder.

Embodiment 3

[0058] A medicine for treating focal segmental glomerulosclerosis, the medicine is made of the following raw materials in parts by weight:

[0059] Astaxanthin 25; Ginger 6000.

[0060] The preparation method is as follows:

[0061] (1) Rinse the fresh ginger with water, squeeze the juice after peeling, the supernatant of the gained juice after centrifugation utilizes an ultrafiltration membrane with a cut-off molecular weight of 300 to carry out ultrafiltration, and the resulting filter residue is freeze-dried to obtain freeze-dried ginger juice powder; The filtrate is concentrated under reduced pressure to a small volume and spray-dried to obtain ginger juice spray-dried powder;

[0062] (2) Mix the astaxanthin with the freeze-dried ginger juice powder and the spray-dried ginger juice powder prepared in the step (1), and fully mix them in a blender to obtain the drug powder.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine and pharmacology, in particular to medicine for treating focal segmental glomerulus sclerosis. The medicine is an oral preparation prepared by combining astaxanthin and fresh ginger with the conventional traditional Chinese medicine theory and pharmacology study result and utilizing the modern process measures, and is preferably a capsule or a tablet. Through the verification by pharmacodynamic experiments, the medicine has the ideal treatment effect on glomerulus sclerosis; in addition, the medicine provided by the invention has high safety; the tolerance and the compliance of a patient are high; and the treatment cost is low.

Description

technical field [0001] The invention relates to the fields of medicine and pharmacy, in particular to a medicine for treating focal segmental glomerulosclerosis. Background technique [0002] Focal segmental glomerulosclerosis (FSGS) refers to partial (focal) glomeruli and / or glomerular capillary loops (segments) with focal segmental sclerosis or A type of glomerular disease with hyaline degeneration and no obvious cell proliferation. This disease is a group of clinicopathological syndromes caused by multiple pathogenesis. According to the etiology, it can be divided into primary FSGS, familial or hereditary FSGS, and secondary FSGS. [0003] The pathogenesis of primary FSGS is still unclear, and the pathogenesis of different pathological types may be different. Some scholars have put forward two hypotheses: one is the injury-scar theory, that is, FSGS is considered to be the result of the repair response of the glomerulus after damage, and is a passive process; the other ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/122A61K36/9068A61P13/12
CPCA61K31/122A61K36/9068A61K2236/31A61K2236/51A61K2300/00
Inventor 贺理宇刘国勇
Owner THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com